JP2011506412A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011506412A5 JP2011506412A5 JP2010537508A JP2010537508A JP2011506412A5 JP 2011506412 A5 JP2011506412 A5 JP 2011506412A5 JP 2010537508 A JP2010537508 A JP 2010537508A JP 2010537508 A JP2010537508 A JP 2010537508A JP 2011506412 A5 JP2011506412 A5 JP 2011506412A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- adamantanecarbonylamino
- composition according
- active ingredient
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004480 active ingredient Substances 0.000 claims 25
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 11
- 239000003246 corticosteroid Substances 0.000 claims 10
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 208000027866 inflammatory disease Diseases 0.000 claims 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 6
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims 4
- 102000019034 Chemokines Human genes 0.000 claims 4
- 108010012236 Chemokines Proteins 0.000 claims 4
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims 4
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims 4
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims 4
- 229960002537 betamethasone Drugs 0.000 claims 4
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 4
- 230000031018 biological processes and functions Effects 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- -1 chloro, bromo, iodo, hydroxy Chemical group 0.000 claims 4
- 229960004544 cortisone Drugs 0.000 claims 4
- 229960003957 dexamethasone Drugs 0.000 claims 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 229960002714 fluticasone Drugs 0.000 claims 4
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 4
- 229960000890 hydrocortisone Drugs 0.000 claims 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 229960004584 methylprednisolone Drugs 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 210000000056 organ Anatomy 0.000 claims 4
- 229960005205 prednisolone Drugs 0.000 claims 4
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 4
- 230000006433 tumor necrosis factor production Effects 0.000 claims 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 108010008165 Etanercept Proteins 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 2
- 208000029725 Metabolic bone disease Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 2
- 229960002964 adalimumab Drugs 0.000 claims 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 2
- 229960000590 celecoxib Drugs 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical group C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960000403 etanercept Drugs 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229960000905 indomethacin Drugs 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 229960000598 infliximab Drugs 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000003278 mimic effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 125000005429 oxyalkyl group Chemical group 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 2
- 229960002702 piroxicam Drugs 0.000 claims 2
- 125000005592 polycycloalkyl group Polymers 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 2
- 229960000371 rofecoxib Drugs 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 2
- 229960001940 sulfasalazine Drugs 0.000 claims 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 229960002871 tenoxicam Drugs 0.000 claims 2
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 claims 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000008240 homogeneous mixture Substances 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0724277.9A GB2455539B (en) | 2007-12-12 | 2007-12-12 | Anti-inflammatory compositions and combinations |
| PCT/GB2008/004074 WO2009074794A2 (en) | 2007-12-12 | 2008-12-10 | Anti-inflammatory compositions and combinations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011506412A JP2011506412A (ja) | 2011-03-03 |
| JP2011506412A5 true JP2011506412A5 (enExample) | 2012-02-02 |
Family
ID=39048063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010537508A Pending JP2011506412A (ja) | 2007-12-12 | 2008-12-10 | 抗炎症性組成物および組み合わせ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110150873A1 (enExample) |
| EP (1) | EP2229184A2 (enExample) |
| JP (1) | JP2011506412A (enExample) |
| KR (1) | KR20100113508A (enExample) |
| CN (1) | CN101925354A (enExample) |
| AU (1) | AU2008334501A1 (enExample) |
| BR (1) | BRPI0820967A2 (enExample) |
| CA (1) | CA2708352A1 (enExample) |
| GB (1) | GB2455539B (enExample) |
| RU (1) | RU2010124593A (enExample) |
| WO (1) | WO2009074794A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2418427A (en) | 2004-09-02 | 2006-03-29 | Univ Cambridge Tech | Ligands for G-protein coupled receptors |
| KR102578891B1 (ko) | 2012-05-11 | 2023-09-15 | 주식회사 젬백스앤카엘 | 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물 |
| EP2847213B1 (en) | 2012-05-11 | 2018-01-03 | KAEL-GemVax Co.,Ltd | Anti-inflammatory peptides and composition comprising the same |
| EP2875826B1 (en) | 2012-05-11 | 2017-08-23 | KAEL-GemVax Co.,Ltd | Composition for preventing or treating sepsis |
| ES2981865T3 (es) | 2012-07-11 | 2024-10-10 | Gemvax & Kael Co Ltd | Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo |
| US20150125438A1 (en) | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
| WO2014171792A1 (ko) | 2013-04-19 | 2014-10-23 | 주식회사 카엘젬백스 | 허혈성 손상 치료 및 예방용 조성물 |
| CN105535931A (zh) | 2013-06-07 | 2016-05-04 | 凯尔杰姆维克斯有限公司 | 在癌症免疫疗法中有用的生物标记 |
| TWI539960B (zh) | 2013-06-21 | 2016-07-01 | 凱爾傑姆維克斯有限公司 | 激素分泌調節劑、包括其的組成物以及其用途 |
| CN105899224B (zh) | 2013-10-23 | 2019-12-13 | 珍白斯凯尔有限公司 | 用于治疗和预防良性前列腺增生的组合物 |
| KR102494803B1 (ko) | 2013-11-22 | 2023-02-06 | 주식회사 젬백스앤카엘 | 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
| ES2809251T3 (es) | 2013-12-17 | 2021-03-03 | Gemvax & Kael Co Ltd | Composición para tratar cáncer de próstata |
| EP3130345B9 (en) | 2014-04-11 | 2022-05-04 | Gemvax & Kael Co., Ltd. | Peptide having fibrosis inhibitory activity and composition containing same |
| ES2962532T3 (es) | 2014-04-30 | 2024-03-19 | Gemvax & Kael Co Ltd | Composición para el trasplante de órganos, tejidos o células, kit y procedimiento de trasplante |
| KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
| EP3263122B1 (en) | 2015-02-27 | 2020-05-06 | Gemvax & Kael Co., Ltd. | Peptide for preventing hearing loss, and composition comprising same |
| WO2017003267A1 (ko) | 2015-07-02 | 2017-01-05 | 주식회사 젬백스앤카엘 | 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물 |
| WO2017176087A1 (ko) | 2016-04-07 | 2017-10-12 | 주식회사 젬백스앤카엘 | 텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물 |
| CN119074923B (zh) * | 2024-04-30 | 2025-11-25 | 中国科学技术大学 | Adra2a拮抗剂在制备治疗炎性肠病的药物中的用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5872145A (en) * | 1996-08-16 | 1999-02-16 | Pozen, Inc. | Formulation of 5-HT agonist and NSAID for treatment of migraine |
| CA2363067C (en) * | 1999-01-12 | 2012-03-20 | David J. Grainger | Compounds and methods to inhibit or augment an inflammatory response |
| TW200307667A (en) * | 2002-05-06 | 2003-12-16 | Bristol Myers Squibb Co | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors |
| EP1594471B1 (en) * | 2003-02-20 | 2009-03-25 | Constant Research & Development Limited | Process for manufacturing a dexamethasone-containing formulation for oral administration |
| CA2547651C (en) * | 2003-12-01 | 2015-06-23 | Cambridge University Technical Services Limited | Anti-inflammatory agents |
| CA2550540A1 (en) * | 2003-12-22 | 2005-07-28 | Schering Corporation | Isothiazole dioxides as cxc- and cc- chemokine receptor ligands |
| CA2554709C (en) * | 2004-01-30 | 2011-11-15 | Schering Corporation | Crystalline polymorphs of a cxc-chemokine receptor ligand |
| WO2005113534A2 (en) * | 2004-05-12 | 2005-12-01 | Schering Corporation | Cxcr1 and cxcr2 chemokine antagonists |
| GB2418425B (en) * | 2004-08-11 | 2008-09-03 | Univ Cambridge Tech | Anti-inflammatory agents |
| GB2418426A (en) * | 2004-08-18 | 2006-03-29 | Univ Cambridge Tech | Alpha-(acylamino)-bicyclolactam derivatives for treatment of inflammatory disorders |
| GB2418427A (en) * | 2004-09-02 | 2006-03-29 | Univ Cambridge Tech | Ligands for G-protein coupled receptors |
| CA2598460C (en) * | 2005-02-16 | 2013-05-07 | Schering Corporation | Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity |
| MX2007010068A (es) * | 2005-02-16 | 2007-10-10 | Schering Corp | Piperazino-piperidinas con actividad antagonista de cxcr3. |
| GB0512238D0 (en) * | 2005-06-15 | 2005-07-27 | Univ Cambridge Tech | Anti-inflammatory agents |
| EP1896036B1 (en) * | 2005-06-15 | 2013-01-23 | Cambridge Enterprise Limited | Anti-inflammatory agents |
| US7781437B2 (en) * | 2005-10-11 | 2010-08-24 | Schering Corporation | Substituted heterocyclic compounds with CXCR3 antagonist activity |
| US7662967B2 (en) * | 2007-08-02 | 2010-02-16 | Cambridge Enterprise Limited | Anti-inflammatory compounds and compositions |
| GB2452696B (en) * | 2007-08-02 | 2009-09-23 | Cambridge Entpr Ltd | 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions |
-
2007
- 2007-12-12 GB GB0724277.9A patent/GB2455539B/en not_active Expired - Fee Related
-
2008
- 2008-12-10 BR BRPI0820967-7A patent/BRPI0820967A2/pt not_active IP Right Cessation
- 2008-12-10 RU RU2010124593/15A patent/RU2010124593A/ru not_active Application Discontinuation
- 2008-12-10 AU AU2008334501A patent/AU2008334501A1/en not_active Abandoned
- 2008-12-10 KR KR1020107015142A patent/KR20100113508A/ko not_active Withdrawn
- 2008-12-10 CA CA2708352A patent/CA2708352A1/en not_active Abandoned
- 2008-12-10 CN CN2008801257773A patent/CN101925354A/zh active Pending
- 2008-12-10 US US12/747,878 patent/US20110150873A1/en not_active Abandoned
- 2008-12-10 WO PCT/GB2008/004074 patent/WO2009074794A2/en not_active Ceased
- 2008-12-10 JP JP2010537508A patent/JP2011506412A/ja active Pending
- 2008-12-10 EP EP08858791A patent/EP2229184A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010124593A (ru) | Противовоспалительные композиции и комбинации | |
| Gao et al. | Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis | |
| Jasiak et al. | Immunosuppression in solid-organ transplantation: essentials and practical tips | |
| JP2017081959A (ja) | 免疫関連疾患及び炎症性疾患の治療における３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンの使用 | |
| JP2007519649A5 (enExample) | ||
| CN103827120A (zh) | 6H-噻吩并[3,2-f][1,2,4]三唑并[4,3-a][1,4]二氮杂* | |
| JP2015057436A5 (enExample) | ||
| JP2012514606A (ja) | Ｈｃｖ治療のためのシクロスポリン誘導体およびヌクレオシドの配合 | |
| WO2000064478A1 (en) | Preventives/remedies for liver diseases | |
| RU2007120454A (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
| CN105050624A (zh) | 利用阿普斯特来治疗银屑病关节炎的方法 | |
| JP2002537258A5 (enExample) | ||
| SK7502002A3 (en) | Pharmaceutical combinations | |
| Mottershead et al. | Daclizumab | |
| JP6878596B2 (ja) | Ｆｘｒアゴニストの組合せ | |
| EP1488808B1 (en) | Remedies for glomerular diseases | |
| TWI606826B (zh) | 艾拉莫德或其鹽之用途 | |
| KR20090125246A (ko) | 전신성 에리테마토데스의 예방 및/또는 치료제 | |
| JP2005281283A (ja) | ベンズイミダゾール系薬剤の併用医薬 | |
| WO2001058443A1 (fr) | INHIBITEURS DE TNF-$g(a) | |
| JP2008509210A5 (enExample) | ||
| RU2322238C2 (ru) | Лечение ревматоидного артрита | |
| JP2020502106A5 (enExample) | ||
| JP2008543822A5 (enExample) | ||
| JP2008509974A5 (enExample) |